Literature DB >> 14634394

Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.

Alexander Haese1, Markus Graefen, Thomas Steuber, Charlotte Becker, Joachim Noldus, Andreas Erbersdobler, Edith Huland, Hartwig Huland, Hans Lilja.   

Abstract

PURPOSE: We measured concentrations of human glandular kallikrein 2 (hK2), total prostate specific antigen (tPSA), free PSA (fPSA) and percent fPSA to evaluate their relationship to total prostate gland volume, benign prostatic hyperplasia (BPH) volume, total prostate cancer (PCa) volume (CaVol) and the volume of Gleason grades 4/5 cancer (CaVolGl4) in the serum of 256 patients with PCa undergoing radical retropubic prostatectomy and 185 with negative systematic sextant biopsies.
MATERIALS AND METHODS: Free and total PSA was measured using the Delfia Prostatus (Perkin-Elmer, Turku, Finland) total/free PSA assay and hK2 was measured using a research immunofluorometric assay. Transrectal ultrasound was used to determine total prostate and BPH volume. Total CaVol and CaVolGl4/5 were calculated using a volumetric program in specimens from 158 men with pT2a/b and 98 with pT3a or greater PCa. The Pearson correlation was performed after logarithmic conversion of PSA and hK2 levels. Benign gland, and pT2a/b and pT3a or greater PCa cases were subdivided into small vs large prostate gland volumes (42 cc or less vs greater than 42 cc).
RESULTS: Total prostate and BPH volumes correlated closely with free PSA (r = 0.64 to 0.65, p <0.0001) in 143 patients with negative biopsy and a prostate of greater than 42 cc. Correlations of hK2 and tPSA with total prostate and BPH volumes were weaker (r = 0.35 to 0.36 and 0.45 to 0.46, respectively). In pT2a/b and pT3a or greater PCa cases hK2 most closely correlated with CaVol (range 0.31 to 0.62, p = 0.0072 and <0.0001) and with CaVolGl4/5 (range 0.26 to 0.56, p = 0.021 and <0.0001, respectively). The tPSA level correlated significantly with CaVol and CaVolGl4/5 except in glands 42 cc or greater harboring pT2a/b PCa (p = 0.08). Free PSA correlated significantly with CaVolGl4/5 only in pT3a or greater PCa (p <0.05), and with CaVol in pT3a or greater PCa and in small prostates harboring pT2a/b PCa.
CONCLUSIONS: Large benign prostate gland volume affects fPSA more than tPSA in serum. In PCa hK2 more closely correlates with total cancer volume and high grade PCa volume compared with tPSA or fPSA.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14634394     DOI: 10.1097/01.ju.0000095794.04551.0c

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.

Authors:  Thomas Steuber; Andrew J Vickers; Alexander Haese; Charlotte Becker; Kim Pettersson; Felix K-H Chun; Michael W Kattan; James A Eastham; Peter T Scardino; Hartwig Huland; Hans Lilja
Journal:  Int J Cancer       Date:  2006-03-01       Impact factor: 7.396

2.  Exploratory study of a KLK2 polymorphism as a prognostic marker in prostate cancer.

Authors:  Manish Kohli; Paul G Rothberg; Changyong Feng; Edward Messing; Jean Joseph; Sreevidya Sadasiva Rao; Allison Hendershot; Deepak Sahsrabudhe
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

3.  Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses.

Authors:  David Ulmert; Andrew J Vickers; Howard I Scher; Charlotte Becker; Peter Iversen; David Frankel; Jens-Kristian Jensen; Tine Kold Olesen; Hans Lilja
Journal:  Clin Chem Lab Med       Date:  2012-11       Impact factor: 3.694

4.  Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk?

Authors:  Sigrid V Carlsson; Mari T Peltola; Daniel Sjoberg; Fritz H Schröder; Jonas Hugosson; Kim Pettersson; Peter T Scardino; Andrew J Vickers; Hans Lilja; Monique J Roobol
Journal:  BJU Int       Date:  2013-02-28       Impact factor: 5.588

Review 5.  Screening for prostate cancer: an update.

Authors:  Shahrokh F Shariat; Peter T Scardino; Hans Lilja
Journal:  Can J Urol       Date:  2008-12       Impact factor: 1.344

Review 6.  Circulating biomarkers for prostate cancer.

Authors:  Thomas Steuber; Pauliina Helo; Hans Lilja
Journal:  World J Urol       Date:  2007-03-08       Impact factor: 4.226

7.  Multivariate gene expression analysis reveals functional connectivity changes between normal/tumoral prostates.

Authors:  André Fujita; Luciana Rodrigues Gomes; João Ricardo Sato; Rui Yamaguchi; Carlos Eduardo Thomaz; Mari Cleide Sogayar; Satoru Miyano
Journal:  BMC Syst Biol       Date:  2008-12-05

Review 8.  Current status of biomarkers for prostate cancer.

Authors:  Vicki M Velonas; Henry H Woo; Cristobal G dos Remedios; Stephen J Assinder
Journal:  Int J Mol Sci       Date:  2013-05-24       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.